Skip to main content
Smart Investors Daily
SL

NASDAQ · SLIM

The Obesity ETF

Financial Services · Asset Management - Global

$33.25

Down-$2.91 (-8.06%)

Updated Sep 16, 2026, 3:53 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
11.34M
P/E ratio
Dividend yield
0.00%
52-week range
— – —
Volume
6.31K
Avg. volume
0

Price performance

SLIM price history

1M range · 0 trading sessions · Daily adjusted prices

SLIM does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SLIM news

The latest Smart Investors Daily articles mentioning SLIM.

SLIM research

Overview

Company profile and research snapshot.

Company profile

The investment seeks investment results that correspond generally to the performance, before fees and expenses, of an index which is designed to track the performance of companies globally that are positioned to profit from servicing the obese, including biotechnology, pharmaceutical, health care and medical device companies whose business is focused on obesity and obesity related disease and companies focused on weight loss programs, weight loss supplements, or plus sized apparel. The fund invests at least 80% of its net assets in the stocks that comprise the Solactive Obesity Index. It is non-diversified.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Dec 11, 2025

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show early efficacy in BMI and hyperphagia reduction, though limited by small sample size and responder heterogeneity. RYTM's HO sNDA PDUFA was delayed to March 2026 for additional FDA analysis, but I remain optimistic on approval with some risk to pediatric labeling.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.